Great Basin Corporation Opens New, Expanded Manufacturing Facility to Meet Market Demand for Low-Cost, Easy-to-Use Molecular Diagnostics Tests Company Also Augments Staff with Sales and Support Personnel Business Wire SALT LAKE CITY -- November 13, 2012 Great Basin Corporation, a privately-held molecular diagnostics company developing sample-to-result solutions, today announced the opening of a new manufacturing facility. Dedicated to the manufacture of the company’s closed-system molecular diagnostics cartridges, the facility more than triples the company’s manufacturing capacity and is located adjacent to Great Basin’s administrative and R&D facility in Salt Lake City. Currently, the company is in full production manufacturing Clostridium difficile (C. diff) molecular diagnostic assay cards used in the company’s Portrait Analyzer. The new facility offers expansion capabilities to support future manufacturing needs for the company’s aggressive product roadmap of molecular assays to aid in the diagnosis of other critical hospital- acquired infections. The company received approval from the U.S. Food and Drug Administration (FDA) for its first product, a molecular diagnostic test for C. diff, at the beginning of May. In the five months following receipt of FDA clearance, the company has exceeded both sales and customer acquisition targets. “Great Basin is experiencing impressive early sales success with our C. diff assay,” said Ryan Ashton, president and CEO of Great Basin Corporation. “Based on the overwhelming demand for our platform, we believe there is a critical need in the market for an information-rich and low-cost test platform that offers a significantly simplified workflow. This new manufacturing facility will allow us to quickly ramp-up production to meet growing demand while delivering the high level of quality and customer service to which Great Basin is committed.” The company also announced the addition of key personnel to support sales and project implementation objectives. New key hires recently added to the Great Basin team include: *Lisa Weingartner, Regional Business Director, Southeast – Ms. Weingartner comes to Great Basin most recently from Lineagen where she held the position of Regional Business Director.At Lineagen, Weingartner finished 2011 as the #1 Regional Business Director and continued to hold that #1 ranking in 2012.Prior to Lineagen, Weingartner worked for Genoptix, Athena Diagnostics, Specialty Labs, and Myriad Genetics.Weingartner will be directing Great Basin’s US commercialization efforts in the Southeast region. *Richard Corbiel, Applications Specialist. Mr. Corbiel comes to Great Basin most recently from BD Diagnostics where he managed their team of Molecular Client Consultants. In this role Corbiel coordinated field trainings and sales support for the U.S.Prior to his work at BD, Corbiel held similar positions at GeneOhm Sciences, Biomerieux and Gen-Probe. At Great Basin, Corbiel will be responsible for client implementation, training and support to assure client success. The company intends to begin clinical trials for its Staph ID/R assay in early 2013. Its automated DNA multiplex assay can identify major pathogenic strains of Staphylococcus to the species level as well as the presence or absence of the methicillin-resistance determinant gene, mecA. Once the clinical trials are completed, the company anticipates FDA clearance and CE-IVD product marketing in Q2 of 2013. About Great Basin Corporation Great Basin Corporation is a privately-held molecular diagnostics company that commercializes breakthrough chip-based technologies. The company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. By providing more diagnostic data per sample, healthcare providers are able to treat patients with the right medication sooner, improving outcomes and reducing costs. The company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company’s website at www.gbscience.com. Contact: Great Basin Corporation Sandra Nielsen, 801-990-1055 firstname.lastname@example.org or Edelman Jennifer Chan, 415-229-7650 email@example.com
Great Basin Corporation Opens New, Expanded Manufacturing Facility to Meet Market Demand for Low-Cost, Easy-to-Use Molecular
Press spacebar to pause and continue. Press esc to stop.